E. L. Miranda

Control transformations through Petri Nets

E. L. Miranda, 1989, SOEN.

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

E. L. Miranda, S. Loi, A. Bardia, 2021 .

Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

E. L. Miranda, G. Curigliano, A. Prat, 2020, Poster Session Abstracts.